IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Active, not recruiting · NCT05359445 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cancer, neoplasm, refractory malignant neoplasm | Active, not recruiting | Phase 1 | 2026-04-30 | NCT05359445 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Immatics Biotechnologies GmbH | 2 |
21 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.